MedSwitcher
FDA-ApprovedInjectable pen (subcutaneous)

Saxenda

liraglutide 3mg · Novo Nordisk

Key Facts

Form

Injectable pen (subcutaneous)

Frequency

Once daily

Available Doses

0.6mg1.2mg1.8mg2.4mg3mg

FDA Approval Date

December 23, 2014

Mechanism

GLP-1 receptor agonist

Manufacturer

Novo Nordisk

Cost

Self-Pay

$1,349/mo

List Price

$1,349/mo

Often not covered by insurance for weight loss. Manufacturer savings available for some eligible patients.

Side Effects

Side EffectRateSource
Nausea~39%SCALE trials
Diarrhea~21%
Constipation~19%
Vomiting~16%
Injection site reactions~14%
Headache~14%

Source: SCALE Clinical Trial Program

Weight Loss Results

SCALE Obesity and Prediabetes

8% (ITT)

56 weeks · Treatment regimen (ITT)

56 weeks

At 3mg dose vs placebo. Lower efficacy than newer GLP-1s but was groundbreaking at time of approval.

How It Works

Liraglutide is a GLP-1 receptor agonist: it mimics the incretin hormone GLP-1, acting on receptors in the brain to reduce appetite and increase satiety, and slowing gastric emptying so meals feel more filling. These effects support lower calorie intake and weight loss when used with diet and exercise.

Mechanism: Saxenda was the first GLP-1 approved for weight management. It uses liraglutide at 3mg/day (vs 1.8mg in Victoza for diabetes). While surpassed in efficacy by semaglutide and tirzepatide, it remains available and is sometimes prescribed when newer options are unavailable or not covered.

Who It's For

Indication

Chronic weight management in adults with BMI ≥30 or ≥27 with weight-related comorbidity

Adults who cannot access or tolerate newer GLP-1 medications. Saxenda has the longest real-world safety track record among weight-loss GLP-1s (approved 2014). However, newer options (Wegovy, Zepbound, Foundayo) offer significantly better weight loss results.

Food & Water Restrictions

✅ No Restrictions

This medication can be taken at any time of day, with or without food and water.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Clinical trial data referenced comes from published studies and FDA prescribing information. Side effect rates are from specific clinical trials and may not reflect real-world experience. Always consult your healthcare provider before starting, stopping, or switching any medication.